Weave Communications, Inc. (WEAV)
AI stock analysis · as of Aug 20, 2026
Loading microstructure…
Weave Communications is a SMB-focused healthcare SaaS platform (patient communications, payments, AI receptionist) growing revenue ~17% to $239M with 72% gross margins but still unprofitable ($28M net loss, $319M accumulated deficit). The investment question is now almost entirely a merger-arbitrage one: Francisco Partners has agreed to take WEAV private at $7.40/share in all-cash, so the thesis reduces to deal-close probability versus the ~$0.09 spread to the current $7.31 price.
valuationFair — the stock is trading essentially at the $7.40 deal price, so market cap of $585M implies ~2.4x sales and ~29x forward earnings, which is a merger-arb clearing price, not a fundamentals-driven multiple.
This analysis is from Aug 20, 2026. Want the latest on WEAV, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Signed definitive all-cash take-private at $7.40 from Francisco Partners (~$650M EV), a 34% premium — provides a hard floor/ceiling anchor with limited fundamental downside if the deal closes
- · Deal is all-cash with a strategic PE sponsor (no financing/stock-mix risk from a public acquirer), and there is no indication of antitrust complexity given WEAV's small size and fragmented competitive set
- · Underlying business is executing: 17% revenue growth, gross margin expanded to 72.4%, and FCF turned positive at $12.9M (6.7% FCF yield) — supports deal certainty and could invite a topping bid, however unlikely
- · Balance sheet is clean ($55M cash vs $52M debt, undrawn revolver) — no distress that would give the acquirer leverage to renegotiate lower
- · 93.8% institutional ownership means a concentrated, sophisticated holder base likely to vote the deal through at a 34% premium
Bear case
- · Upside is now capped at ~$7.40 (roughly 1.2% spread from $7.31), so risk/reward is highly asymmetric — deal break would likely send shares back toward pre-announcement levels (~$5.50), a ~25% downside vs ~1% upside
- · 3 analyst downgrades in the last 90 days with 0 upgrades; the most recent was B. Riley Securities on 2026-08-19 (note: news text describes B. Riley as initiating buy — data source conflict worth flagging)
- · Standalone fundamentals do not clearly justify $7.40 absent the bid: EV/EBITDA is negative (-58x), forward P/E of 29.7x is rich for a company with -8% net margins, and the company has $319M in accumulated deficit with no clear GAAP profitability date
- · SMB healthcare customer base is on month-to-month contracts with high churn exposure — a macro softening between signing and close could give Francisco Partners a MAC argument
- · Debt-to-equity of 60.5x reflects a thin equity base; ROE of -25% underscores that capital efficiency has not yet been proven
- · Short interest at 7.3% of float / 4.6 days to cover — elevated but consistent with typical merger-arb positioning rather than a directional short thesis
Catalysts
- · Shareholder vote and regulatory clearance for the Francisco Partners deal — the dominant catalyst
- · Any interloper / topping bid (low probability but not zero given the modest 34% premium for a growing SaaS asset)
- · Q3 earnings on 2026-11-05 — likely a non-event given the pending deal but could reveal MAC-relevant business trends
- · Deal close and NYSE delisting timeline confirmation
- · Any HSR second-request or regulatory delay news that would widen the arb spread
Key risks
- · Deal break risk — regulatory, financing, or MAC-driven — would collapse the stock back toward mid-$5s
- · Extended time-to-close eroding annualized arb return even if deal closes at $7.40
- · Deterioration in SMB healthcare demand between signing and close, giving the buyer a MAC lever
- · Data source inconsistency on analyst actions (downgrades data vs news commentary on B. Riley) suggests thesis inputs should be verified against primary sources
- · As a private-going deal, remaining public shareholders have no long-term equity participation in AI/payments upside
What to watch
- · Merger proxy filing and shareholder vote date
- · HSR waiting period expiration and any second-request signals
- · Q3 earnings on 2026-11-05 for any MAC-relevant deterioration
- · Arb spread widening beyond ~2% as an early warning of deal risk
- · Any 13D/13G filings suggesting an activist pushing for a higher price
- · Confirmation of B. Riley's actual stance given conflicting data between downgrade log and news summary
Key metrics
Price target rationale
Base case is the $7.40 announced deal price assuming standard close. Bull case ($7.75) assumes a modest topping bid (~5% bump) which is possible but unlikely given no reported interloper. Bear case ($5.50) assumes deal break, with the stock reverting toward pre-announcement levels (~$5.50 implied by a 34% premium to $7.40).
On Wall Street's view (agree): The $8.00 consensus target modestly exceeds the $7.40 deal price, which is either stale or reflects hope of a topping bid; we think $7.40 is the realistic ceiling and the current ~$7.31 price fairly reflects deal-close probability minus time value.
Latest filing (10-K)
Weave is a profitable-in-sight SMB healthcare SaaS platform growing revenue 17% annually to $239M, but still burning cash with a $319M accumulated deficit as it bets on AI upsell and payments attach to finally close the gap.
Weave Communications is an AI-powered patient communications, engagement, and payments platform purpose-built for SMB healthcare practices (dental, optometry, veterinary, specialty medical). The company generates revenue primarily through recurring SaaS subscriptions and payment processing fees, with a smaller contribution from phone hardware sales and onboarding fees. As of December 31, 2025, Weave served nearly 40,000 locations and more than 30,000 customers across the U.S. and Canada.
What the news says · bullish
The dominant storyline is a definitive take-private acquisition of Weave Communications by Francisco Partners for $7.40 per share in an all-cash deal valuing the company at approximately $650 million — a 34% premium to the pre-announcement price. The news triggered a ~31% single-day surge in the stock. With the deal price now acting as a hard ceiling, upside is essentially capped at the spread between the current trading price and $7.40, making this a merger-arbitrage situation rather than a growth story. Loop Capital's downgrade on the acquisition news reflects the standard analyst response when a stock becomes a closed-end deal, while B. Riley's same-day buy initiation likely reflects confidence the deal closes. Shareholders face NYSE delisting upon deal completion, and the key remaining risk is deal execution/regulatory approval.
This analysis is from Aug 20, 2026. Markets move. Get the current read on WEAV and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.